Yes needle, great PI3K/mTOR research and reasoning revealed in...

Yes needle, great PI3K/mTOR research and reasoning revealed in this latest publication.
Paxalisib's full potential patient benefits are to be progressively revealed, as previously discussed over the next 18 months.

..................................................................................................
Note : Another large phase 3 trial for the glioblastoma, published 14 April 2022. Buried in the glioblastoma graveyard.
IMO the GBM AGILE data will be sufficient for an FDA approval next year for for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter.

Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.

CONCLUSIONS
The study did not meet the primary endpoint of improved OS; TMZ+RT demonstrated a longer median OS than NIVO+RT. No new safety signals were detected with NIVO in this study. The difference between the study treatment arms is consistent with the use of TMZ+RT as standard of care for glioblastoma.

https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noac099/6568419?login=false

Regards.